• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»triple negative breast cancer

How Cellectar Biosciences, Inc. is positioning CLR 125 for a differentiated TNBC treatment thesis

By Soujanya Ravi on April 14, 2026   Pharma & Biotech  

How Cellectar Biosciences, Inc. is positioning CLR 125 for a differentiated TNBC treatment thesis

Cellectar Biosciences, Inc. begins CLR 125 Phase 1b in refractory TNBC. Read what this could mean for precision radioconjugate oncology.

Can ultrasensitive ctDNA monitoring reshape how clinicians track neoadjuvant breast cancer therapy response?

By Pallavi Madhiraju on March 15, 2026   Medical Devices & Diagnostics  

Can ultrasensitive ctDNA monitoring reshape how clinicians track neoadjuvant breast cancer therapy response?

New PREDICT-DNA data suggests ultrasensitive ctDNA monitoring may outperform traditional markers in breast cancer relapse prediction. Read the full analysis.

Recent Posts

  • Can Nektar’s 52-week REZOLVE-AA update strengthen the case for rezpegaldesleukin in alopecia areata?
  • Can Whitehawk Therapeutics turn preclinical ADC depth into a real oncology pipeline advantage?
  • Medtronic backs Pulnovo Medical in $100m round to expand PADN in pulmonary hypertension
  • Why CStone Pharmaceuticals’ CS5007 may be the most important asset in its AACR 2026 antibody-drug conjugate update
  • Orthogon Therapeutics adds $11m for BK virus drug, targeting one of transplant medicine’s toughest gaps
  • LEO Pharma wins China approval for Enstilar, but can topical psoriasis leadership scale in the world’s biggest patient market?
  • Obodence at WCO 2026: Samsung Bioepis sharpens the clinical case for SB16 adoption
  • Khondrion moves sonlicromanol into Phase 3, but can KHENERFIN finally crack mitochondrial disease?
  • Why Bruker’s ESCMID 2026 microbiology expansion could matter for hospital labs and infection control
  • Can Byondis turn novel ADC payload chemistry into a real edge in resistant cancers?
  • Drug Farm’s DF-003 shows early signal in ROSAH syndrome, but can ALPK1 inhibition hold up in pivotal testing?
  • Why MyGenius PRO could strengthen Bruker’s position in automated infectious disease diagnostics
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes